Page 17 - Pharma Sector

Chemists' association seeks meeting with NPPA over price display issue

The NPPA, in an office memorandum (OM) dated February 4, had directed medicine retailers as well as online pharmacies to "conspicuously" display current drug price list

Medicine retailers, e-pharmacies asked to display DPCO's drug price list

National pharma pricing regulator says list has to be put up 'conspicuously'

Steel, pharma, chemicals: Top Indian sectors at risk of higher US tariffs

Countries that have free trade agreements with the US, such as Singapore and South Korea, are safer with respect to Trump's reciprocal tariff threat, analysts at Nomura said.

AstraZeneca's cancer drug tops list of new brands launched in 2024

Five of top 20 drug introductions target cancer, reflecting its rising incidence in India

Alkem Labs, Ipca, Divi's: Three reasons why pharma stocks are falling today

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

Pharma exports to touch $65 bn mark by 2030, $350 bn by 2047: Report

India's pharma exports are expected to double to USD 65 billion by 2030 and touch USD 350 billion in value terms by 2047, moving to top five position globally by diversifying its product basket, according to a report. While India is the largest supplier of generic drugs globally, accounting for one in five generic drugs sold worldwide, the nation ranks 11th in terms of export value. As per the Bain & Company's report, 'Healing the World: Roadmap for Making India a Global Pharma Exports Hub', India can potentially secure a position among the top five nations in export value by 2047 by innovating and diversifying its export basket to include specialty generics, biosimilars, and innovative products. The findings in the report were formulated in collaboration with Indian Pharmaceutical Alliance (IPA), Indian Drugs Manufacturers' Association (IDMA), and Pharmexcil. "The transition from volume-based to value-led growth is essential for Indian pharma to secure its rightful place in the ..

Indian pharma market registers over 8% growth in January 2025: Pharmarack

Among them, the cardiac, anti-diabetic, and gastrointestinal therapies saw high value growth of 10.9 per cent, 10.2 per cent, and 6.9 per cent, respectively, driving overall IPM growth

Lilly forecasts 2025 profit above estimates on weight-loss drug strength

The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug Zepbound for the second straight quarter

Zydus Life up 3% on mixed Q3, mcap tops Rs 1 trn; analysts split on outlook

Despite challenges from a lower-margin product mix, Zydus Life benefitted from forex gains and a favourable tax rate, which led to a PAT beat, analysts said

ICMR initiates process of vaccine development against avian influenza

The ICMR has initiated the process of development of an ingenious human vaccine candidate against highly-pathogenic avian influenza (H5N1). The Indian Council of Medical Research (ICMR) has invited expression of interest from the eligible organisations, companies, manufacturers for joint collaboration in research and development for development of human vaccine candidate against H5N1. The avian influenza H5N1, a highly pathogenic strain of bird flu, continues to pose a significant threat to animal and human health in India. Recent outbreaks in 2021, 2023 and 2024 have been reported in several states, primarily affecting poultry and wild birds, the expression of interest document said. These outbreaks have caused significant economic losses in the poultry industry and raised public health concerns due to the virus's zoonotic potential, it said. The document stated that avian influenza H5N1 virus poses a grave public health risk because of its high mortality rate and its potential t

Pfizer beats profit estimates on heart disease drug, Covid vaccine sales

Pfizer is facing investor pressure to show that its recent acquisitions and investments can bring in returns

3 firms divest 6.8% stake in Onesource Specialty Pharma for Rs 1,202 crore

Three entities, including two promoters of Onesource Specialty Pharma, on Friday divested a 6.8 per cent stake in the company for Rs 1,202 crore through open market transactions. Tenshi Pharmaceuticals (Promoter) and Pronomz Ventures LLP (Promoter Group) and Medella Holdings Pte Ltd were the entities who have offloaded 77.66 lakh shares or 6.8 per cent stake in Bengaluru-based Onesource Specialty Pharma, as per the bulk deal data available on the NSE. The shares were disposed of in the price range of Rs 1,545-1,552.90 apiece, taking the combined value to Rs 1,202.23 crore. The promoters of the company divested a 3.4 per cent stake in the firm. After the latest transaction, the combined shareholding of promoter holding in Onesource Specialty Pharma has come down to 34.36 per cent from 37.77 per cent and Medella Holdings stake has declined to 0.8 per cent from 4.17 per cent. Meanwhile, Motilal Oswal Mutual Fund and CPT Research & Mgmt Co T/A CPT World Investors acquired 21.95 lakh .

Biocon Biologics plans IPO for biosimilars business by Mar 2026: CEO

The company, which has been pushing its IPO plans for the past year, has been waiting to complete the integration of its acquired biosimilars firm Viatris and refinance debt before it goes public

Ajanta Pharma Q3 results: Net profit increases 11% to Rs 233 crore

Ajanta Pharma on Thursday said its consolidated profit after tax increased by 11 per cent on-year to Rs 233 crore for the third quarter ended December 31, 2024. The drug firm had reported a profit after tax (PAT) of Rs 210 crore in the October-December period of last fiscal. Revenue from operations stood at Rs 1,146 crore in the third quarter compared to Rs 1,105 crore in the year-ago period, Ajanta Pharma said in a regulatory filing. Shares of the company settled 1.64 per cent higher at Rs 2,670.70 apiece on the BSE.

Cigna falls short of Q4 profit estimates due to higher medical costs

The plan, called "stop-loss insurance", entails the insurer covering for employers' self-funded plans when their costs surpass a certain threshold due to catastrophic or unexpected medical claims

Dr Lal Path Labs Q3FY25 results: Net profit jumps 19% to Rs 96.7 crore

The company's consolidated net profit rose to Rs 96.7 crore ($11.2 million) in the three months to Dec. 31, from Rs 81.3 crore a year earlier, but fell short of analysts' estimate of Rs 97.69 crore

Cipla Q3 Preview: Supply disruptions, market share loss to weigh on topline

Cipla Q3 Preview: India's third largest pharmaceutical company, Cipla, is scheduled to deliver its October-December quarterly earnings for the financial year 2024-25 (Q3FY25) on Tuesday, January 28

Flipkart has ended its partnership with us: Medicine e-tailer Sastasundar

Medicine e-tailer Sastasundar on Tuesday said that e-commerce giant Flipkart has ended its partnership in the online pharmacy and healthcare space with it. The Kolkata-based entity also said it has reclaimed its brand's intellectual property rights (IPRs). The Walmart-owned Flipkart had acquired a 75 per cent stake in Sastasundar Marketplace in 2021. An e-mail sent to Flipkart on the development did not elicit any response. "The deal with Flipkart is over and we got back all the intellectual property rights of the Sastasundar brand from it. Now, we will launch our app. In 2021, we had sold a 75 per cent stake in Sastasundar Marketplace Ltd for around Rs 750 crore to Flipkart," Sastasundar Group chairman B L Mittal told PTI. This reclaim transaction did not attract any material investment, he said. Holding company Sastasundar Ventures has re-acquired the brand's IPRs and non-compete rights from Flipkart Health+ through its newly-formed subsidiary, Sastasundar Healthtech Ltd, he ..

Doctors may face suspension in NMC probe over pharma-sponsored trips

This was in violation of the UCPMP rules, which regulate interactions between pharmaceutical companies and HCPs and prohibit foreign trips, gifts, and inducements as unethical marketing practices

Union Budget 2025-26: Customs duty hike likely on key pharma, RE products

Key components in the renewable energy industry such as special bearings, gearboxes, yaw components, wind turbine controllers are currently subjected to a concessional customs duty of 5 per cent